Literature DB >> 1422359

Effect of maintenance chemotherapy in childhood on numbers of melanocytic naevi.

E A Baird1, P M McHenry, R M MacKie.   

Abstract

OBJECTIVE: (a) To determine whether children given chemotherapy for haematological malignancy have significantly more melanocytic naevi than age matched children in the local population; (b) to establish whether any observed variation in naevus counts from normal is seen at the start of maintenance chemotherapy.
DESIGN: Follow up of 29 consecutive children starting maintenance chemotherapy, with parental interview and count of all melanocytic naevi > or = 2 mm on the child's skin. Assessment repeated three years later after completion of maintenance chemotherapy. Other dermatological problems identified at either visit were also recorded.
SETTING: Royal Hospital for Sick Children, Glasgow.
RESULTS: At the start of maintenance chemotherapy all children had total body counts of melanocytic naevi within the normal range established for age matched children in the local population. Three years later total body naevus counts were significantly increased, the median increase being 66 naevi per child (95% confidence interval 57 to 94). The only other problem noted in these children was relatively poor regrowth of scalp hair.
CONCLUSION: Children on maintenance chemotherapy for haematological malignancies develop an excessive number of melanocytic naevi. Excessive numbers of melanocytic naevi are the most important risk factor for melanoma in the general population. These children should have periodic skin examinations at their follow up visits, and both child and parent should be educated about clinical features of early melanoma.

Entities:  

Mesh:

Year:  1992        PMID: 1422359      PMCID: PMC1883498          DOI: 10.1136/bmj.305.6857.799

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  8 in total

1.  Personal risk-factor chart for cutaneous melanoma.

Authors:  R M MacKie; T Freudenberger; T C Aitchison
Journal:  Lancet       Date:  1989-08-26       Impact factor: 79.321

2.  Benign melanocytic naevi as a risk factor for malignant melanoma.

Authors:  A J Swerdlow; J English; R M MacKie; C J O'Doherty; J A Hunter; J Clark; D J Hole
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-14

3.  Excess benign melanocytic naevi after chemotherapy for malignancy in childhood.

Authors:  B R Hughes; W J Cunliffe; C C Bailey
Journal:  BMJ       Date:  1989-07-08

4.  Prevalence of naevocytic naevi after chemotherapy for childhood cancer.

Authors:  P E de Wit; G A de Vaan; T M de Boo; W A Lemmens; F H Rampen
Journal:  Med Pediatr Oncol       Date:  1990

5.  Suntan, sunburn, and pigmentation factors and the frequency of acquired melanocytic nevi in children. Similarities to melanoma: the Vancouver Mole Study.

Authors:  R P Gallagher; D I McLean; C P Yang; A J Coldman; H K Silver; J J Spinelli; M Beagrie
Journal:  Arch Dermatol       Date:  1990-06

6.  Number of melanocytic nevi as a major risk factor for malignant melanoma.

Authors:  E A Holly; J W Kelly; S N Shpall; S H Chiu
Journal:  J Am Acad Dermatol       Date:  1987-09       Impact factor: 11.527

7.  The Danish case-control study of cutaneous malignant melanoma. I. Importance of host factors.

Authors:  A Osterlind; M A Tucker; K Hou-Jensen; B J Stone; G Engholm; O M Jensen
Journal:  Int J Cancer       Date:  1988-08-15       Impact factor: 7.396

8.  The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population.

Authors:  R M MacKie; J English; T C Aitchison; C P Fitzsimons; P Wilson
Journal:  Br J Dermatol       Date:  1985-08       Impact factor: 9.302

  8 in total
  2 in total

1.  Professor Rona MacKie, Scottish dermatologist and melanoma authority.

Authors:  A Daunton; A R Shipman
Journal:  Int J Womens Dermatol       Date:  2015-10-01

2.  Melanocytic naevi and melanoma in survivors of childhood cancer.

Authors:  A Green; P Smith; W McWhirter; P O'Regan; D Battistutta; M E Yarker; K Lape
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.